京神奇药丸通过调节下丘脑胰岛素抵抗以及POMC/AgRP表达和活性来改善糖尿病
Shan Zhang1, Yueying Zhang1, Zhige Wen1
1Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
概括
京神奇药片 (JSP) 通过调节下丘脑中益皮梅拉诺科廷 (POMC) /阿古蒂相关蛋白 (AgRP) 神经元,有效地降低了糖尿病小鼠的血糖. 通过PI3K/AKT/FOXO1通路改善胰岛素敏感性,为糖尿病提供潜在的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 脑下垂体中蛋白质 (POMC) 和蛋白质相关神经元 (AgRP) 的神经元不平衡与糖尿病病理生理学有关.
- 众所周知,Jinkui Shenqi药片 (JSP) 是一种传统的中医药,可以调节下丘脑功能并治疗糖尿病.
研究的目的:
- 在2型糖尿病小鼠模型中研究JSP的低血糖效应.
- 阐明JSP对糖尿病治疗中涉及的下丘脑路径的作用的潜在机制.
主要方法:
- 通过使用体重,食物摄入量,禁食血糖,胰岛素水平和口服葡萄糖耐受性测试来评估JSP的降糖效果.
- 量化了POMC和AgRP的表达/活性,并通过西部涂抹和免疫组织化学分析了糖尿病小鼠的PI3K/AKT/FOXO1通路.
- 在胰岛素抵抗条件下研究了JSP对初级下丘脑神经元的影响.
主要成果:
- 根据剂量,JSP治疗减少了体重,禁食血糖,并提高了葡萄糖耐受性,同时增加了胰岛素水平.
- 在糖尿病小鼠中,JSP保护了下丘脑神经元结构,并增强了树突形态.
- JSP上调了胰岛素介导的PI3K/AKT/FOXO1通路,增加了POMC表达/活性,并在下丘脑中减少了AgRP表达/活性.
结论:
- 通过调节下丘脑POMC/AgRP神经元平衡,JSP可以改善糖尿病.
- PI3K/AKT/FOXO1通路是JSP在下丘脑中抗糖尿病作用的关键调解者.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
Glucagon-like Receptor Agonists
322
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
322
Oral Hypoglycemic Agents: Biguanides and Glitazones
201
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
201
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175


